Here’s how we can make clinical trials more inclusive

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Since COVID-19 made its way to the United States, we have seen a stream of worrying news of the pandemic’s impact on cancer care in the U.S., including 9.4 million missed screenings1 for just about all forms of cancer. While screening rates rebounded in the fall of 20202, there’s a growing concern from oncologists that screenings haven’t returned to pre-pandemic levels for everyone. 

And the data are compelling. From September to December 2020, for example, fewer Black and Hispanic women2 had mammograms than in the three months prior to the pandemic. In addition, Black men were 25% less likely3 than their white counterparts to get a prostatectomy during the pandemic. 

There is significant concern among health equity advocates that the pandemic’s ripple effects on cancer care could be sustaining or even deepening widely recognized and reported health disparities for vulnerable communities, including Black, Latinx, and rural Americans.4 Warnings from experts of the pandemic’s impact on cancer disparities necessitate an even greater urgency to further reduce gaps in care.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Jenny Sherak
Senior vice president & President, Specialty Physician Services AmerisourceBergen
Table of Contents

YOU MAY BE INTERESTED IN

In a phase II clinical trial, a research team led by Nilofer Azad, professor of oncology and co-leader of the Kimmel Cancer Center’s Cancer Genetics and Epigenetics Program, and Marina Baretti, the Jiasheng Chair in Hepato-Biliary Cancer at the Kimmel Cancer Center, tested the safety and efficacy of the combination of two drugs: an immunotherapy, nivolumab, and an epigenetic drug, entinostat—a histone deacetylase inhibitor. 
A group of investigators led by Cedars-Sinai have developed and successfully tested a new artificial intelligence method to make launching cancer clinical trials easier and faster. The method uses patients’ pathology reports to automate the classification of patients by the severity of their cancers, potentially shortening the process of selecting candidates for clinical trials.
Jenny Sherak
Senior vice president & President, Specialty Physician Services AmerisourceBergen

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login